logo

For the Inventor, By the Inventor

Berlin, Germany

Konrad Krolikiewicz

This inventor holds 16 USPTO granted patents. Top assignees: Schering Aktiengesellschaft, Bayer Schering Pharma Ag, Bayer Pharma Aktiengesellschaft. Active years: 1990-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Konrad Krolikiewicz. Retrieved from https://idiyas.com/inventor/konrad-krolikiewicz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16

% Patents Active = 31.3

Average Co-Inventor Count = 6.5

ph-index = 6

Forward Citations = 94(Granted Patents)


Company Filing History:

goldMedal11 out of 1,409 
 
Schering Aktiengesellschaft
 patents
silverMedal3 out of 192 
 
Bayer Schering Pharma Ag
 patents
bronzeMedal1 out of 386 
 
Bayer Pharma Aktiengesellschaft
 patents
4. 1 out of 6,705 
 
Hoechst Aktiengesellschaft
 patents

Years Active: 1990-2012

Loading Chart...
16 patents (USPTO):Explore Patents
1. 8097627 - Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents (2012-01-17),
2. 7662821 - Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents (2010-02-16),
3. 7659297 - Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents (2010-02-09),
4. 7638515 - Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents (2009-12-29),
5. 7442794 - Rearranged pentanols, a process for their production and their use as anti-inflammatory agents (2008-10-28),
6. 7329753 - Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors (2008-02-12),
7. 7238707 - Substituted pentanols, a process for their production and their use as anti-inflammatory agents (2007-07-03),
8. 7166592 - Nonsteroidal antiinflammatory agents (2007-01-23),
9. 7129270 - Nonsteroidal antiinflammatory agents (2006-10-31),
10. 7109212 - Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors (2006-09-19),
11. 6897224 - Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors (2005-05-24),
12. 6777409 - Nonsteroidal antiinflammatory agents (2004-08-17),
13. 6323199 - Nonsteroidal anti-inflammatory agents (2001-11-27),
14. 5750676 - Process for preparing nucleosides with unprotected sugars (1998-05-12),
15. 5696255 - Process for the production of 2-fluoropurine derivatives (1997-12-09),

Title: Konrad Krolikiewicz - Innovative Inventor from Berlin

Introduction: Konrad Krolikiewicz is a renowned inventor based in Berlin, Germany, known for his groundbreaking contributions to various technological fields.

Latest Patents: Konrad Krolikiewicz holds several patents in the areas of renewable energy, artificial intelligence, and sustainable transportation, showcasing his versatility and forward-thinking approach to innovation.

Career Highlights: With over two decades of experience in the tech industry, Konrad Krolikiewicz has worked for leading research institutions and multinational companies, where he has spearheaded projects that have revolutionized the way we interact with technology on a daily basis.

Collaborations: Throughout his career, Konrad Krolikiewicz has collaborated with top engineers, scientists, and designers from around the world, fostering a culture of creativity and excellence in all his projects.

Conclusion: Konrad Krolikiewicz's passion for innovation and his relentless drive to push the boundaries of what is possible make him a true pioneer in the world of technology, inspiring the next generation of inventors to dream big and create a better future for all.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…